PriceSensitive

Pro Medicus launches Visage Ease VP for Apple Vision Pro

ASX News, Health Care
ASX:PME      MCAP $23.17B
05 February 2024 16:18 (AEDT)

Pro Medicus (ASX:PME) shares jumped almost five per cent on its $11.5 billion market cap after announcing it will offer a diagnostic imaging software on Apple’s new Vision Pro virtual reality headset.

The company’s subsidiary, Visage Imaging has launched its Visage Ease VP for Apple headsets, allowing consumers to examine diagnostic images in a virtual, spatial setting.

The Visage Ease VP includes all the proven functionality of PME’s Visage Ease™ software, except patients can view the images anywhere on the go through a virtual screen offering 4K resolution in each eye.

Hands and voice navigation also work to provide an end-user imaging experience that’s unlike any other application, according to Pro Medicus.

Tier one academic medical centre and Visage customer, UC San Diego Health, is the first health system to pilot the technology.

“Visage’s platform of enterprise imaging applications that support the Apple ecosystem are used by many of the world’s largest, most sophisticated healthcare organisations, and also integrated bi-directionally to the most widely used EHR,” Visage Co-Founder and Global Chief Technology Officer Malte Westerhoff said.

“With Visage Ease VP we can now extend our offering to immersive, spatial imaging which has the potential to open up a number of novel and exciting possibilities within both medical imaging and the wider healthcare space.”

The Visage Ease VP is the newest addition to the Visage Ease suite of native apps designed specifically for the Apple ecosystem. It joins Visage Ease (iOS/iPadOS) and Visage Ease Pro™ (iPadOS).

Additionally, Visage provides the highly regarded Visage 7 smart-client app for macOS, offering native, rapid, clinically robust, and highly interoperable access to enterprise imaging.

PME closed at $109.06.

Related News